WCM Investment Management LLC Decreases Stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

WCM Investment Management LLC trimmed its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 5.1% during the fourth quarter, Holdings Channel reports. The institutional investor owned 284,622 shares of the biopharmaceutical company’s stock after selling 15,423 shares during the quarter. WCM Investment Management LLC’s holdings in Halozyme Therapeutics were worth $13,659,000 as of its most recent SEC filing.

Other large investors have also recently made changes to their positions in the company. RPg Family Wealth Advisory LLC acquired a new position in Halozyme Therapeutics during the 3rd quarter worth approximately $1,886,000. Segall Bryant & Hamill LLC lifted its position in shares of Halozyme Therapeutics by 16.3% during the 3rd quarter. Segall Bryant & Hamill LLC now owns 355,176 shares of the biopharmaceutical company’s stock worth $20,330,000 after purchasing an additional 49,856 shares during the last quarter. Retirement Systems of Alabama grew its stake in shares of Halozyme Therapeutics by 23.5% during the third quarter. Retirement Systems of Alabama now owns 389,268 shares of the biopharmaceutical company’s stock worth $22,282,000 after purchasing an additional 74,173 shares in the last quarter. South Street Advisors LLC purchased a new position in Halozyme Therapeutics in the third quarter valued at $9,812,000. Finally, Foster & Motley Inc. raised its stake in Halozyme Therapeutics by 118.6% in the fourth quarter. Foster & Motley Inc. now owns 23,280 shares of the biopharmaceutical company’s stock valued at $1,113,000 after buying an additional 12,630 shares in the last quarter. 97.79% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, Director Jeffrey William Henderson sold 5,000 shares of Halozyme Therapeutics stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $56.30, for a total value of $281,500.00. Following the transaction, the director now directly owns 38,611 shares in the company, valued at $2,173,799.30. This trade represents a 11.46 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Corporate insiders own 2.40% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on HALO shares. HC Wainwright reaffirmed a “buy” rating and set a $70.00 price objective on shares of Halozyme Therapeutics in a research report on Tuesday, February 4th. Wells Fargo & Company lowered their price target on Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating for the company in a report on Monday, January 13th. JMP Securities raised their price objective on shares of Halozyme Therapeutics from $72.00 to $73.00 and gave the stock a “market outperform” rating in a report on Friday, November 1st. Cowen restated a “buy” rating on shares of Halozyme Therapeutics in a research report on Friday, October 18th. Finally, Piper Sandler increased their target price on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the company a “neutral” rating in a research report on Friday, January 10th. Four investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $60.89.

Halozyme Therapeutics Trading Down 1.4 %

NASDAQ HALO opened at $57.10 on Monday. The firm’s fifty day moving average is $51.55 and its two-hundred day moving average is $54.41. Halozyme Therapeutics, Inc. has a one year low of $34.36 and a one year high of $65.53. The company has a debt-to-equity ratio of 3.32, a quick ratio of 9.15 and a current ratio of 10.36. The firm has a market cap of $7.26 billion, a PE ratio of 18.91, a P/E/G ratio of 0.44 and a beta of 1.25.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.